NZ597080A - Modulation of systemic exposure to rifaximin - Google Patents

Modulation of systemic exposure to rifaximin

Info

Publication number
NZ597080A
NZ597080A NZ597080A NZ59708010A NZ597080A NZ 597080 A NZ597080 A NZ 597080A NZ 597080 A NZ597080 A NZ 597080A NZ 59708010 A NZ59708010 A NZ 59708010A NZ 597080 A NZ597080 A NZ 597080A
Authority
NZ
New Zealand
Prior art keywords
rifaximin
modulation
systemic exposure
child
medicament
Prior art date
Application number
NZ597080A
Inventor
William Forbes
Original Assignee
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Ltd
Publication of NZ597080A publication Critical patent/NZ597080A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

NZ 597080 Disclosed is the use of rifaximin for the preparation of a medicament for reducing the risk of overt hepatic encephalopathy (HE) occurrence in a subject, wherein the medicament is formulated for administration between 1000 and 1200 mg of rifaximin daily to the subject if his or her Child-Pugh score is Child-Pugh Class C.
NZ597080A 2009-06-15 2010-06-15 Modulation of systemic exposure to rifaximin NZ597080A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18725109P 2009-06-15 2009-06-15
US29769610P 2010-01-22 2010-01-22
PCT/US2010/038742 WO2010148040A1 (en) 2009-06-15 2010-06-15 Modulation of systemic exposure to rifaximin

Publications (1)

Publication Number Publication Date
NZ597080A true NZ597080A (en) 2014-02-28

Family

ID=43356731

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ597080A NZ597080A (en) 2009-06-15 2010-06-15 Modulation of systemic exposure to rifaximin

Country Status (9)

Country Link
EP (1) EP2442803A4 (en)
KR (1) KR20120030542A (en)
CN (1) CN102625701A (en)
AU (1) AU2010260089B2 (en)
CA (1) CA2765577A1 (en)
MX (1) MX2011013427A (en)
NZ (1) NZ597080A (en)
RU (1) RU2571268C2 (en)
WO (1) WO2010148040A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1698630E (en) 2005-03-03 2014-09-15 Alfa Wassermann Spa New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
ITBO20050123A1 (en) 2005-03-07 2005-06-06 Alfa Wassermann Spa GASTRORESISTIC PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMINA
WO2021152587A1 (en) 2020-01-30 2021-08-05 Yeda Research And Development Co. Ltd. Treating acute liver disease with tlr-mik inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2420226B1 (en) * 2007-07-06 2020-03-04 Lupin Limited Pharmaceutical compositions of rifaximin
AU2008273699A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
US20110035232A1 (en) * 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
EP2350096B1 (en) * 2008-10-02 2019-12-11 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
CN102548408A (en) * 2009-06-02 2012-07-04 萨利克斯药品有限公司 Methods of treating hepatic encephalopathy

Also Published As

Publication number Publication date
EP2442803A4 (en) 2012-11-28
RU2571268C2 (en) 2015-12-20
RU2012101310A (en) 2013-07-27
KR20120030542A (en) 2012-03-28
CN102625701A (en) 2012-08-01
EP2442803A1 (en) 2012-04-25
AU2010260089B2 (en) 2015-05-14
CA2765577A1 (en) 2010-12-23
MX2011013427A (en) 2012-04-20
WO2010148040A1 (en) 2010-12-23
AU2010260089A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
NZ594207A (en) Immediate release composition resistant to abuse by intake of alcohol
TN2012000428A1 (en) Bisaryl-bonded aryltriazolones and use thereof
MX2009013427A (en) Use of estriol in low doses.
MX2009003372A (en) Non-mucoadhesive film dosage forms.
WO2009008001A3 (en) Inhalation device
CU20110100A7 (en) PIRFENIDONE TREATMENT FOR PATIENTS WITH ATYPIC HEPATIC FUNCTION
ATE524570T1 (en) METAL FOIL
WO2007107305A3 (en) Treatment of triple receptor negative breast cancer
IL201479A (en) Use of tapentadol for the manufacture of a medicament for the treatment of pain
MY160768A (en) Use of salvia miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease
NZ596851A (en) Methods of treating hepatic encephalopathy
NZ600874A (en) Fluorinated derivatives of deferiprone
NZ630494A (en) Administration of lorcaserin to individuals with renal impairment
MX2010000266A (en) A method for decreasing symptoms of alcohol consumption.
CR20110243A (en) PIRFENIDONE TREATMENT FOR PATIENTS WITH HEPATIC FUNCTION.
MX2009011900A (en) Diabetic wound healing.
WO2008106689A3 (en) Breakthrough pain management
ZA201007391B (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium in the blood
NZ597080A (en) Modulation of systemic exposure to rifaximin
WO2009001209A8 (en) Use of conjugates of hyaluronic acid in the local treatment of hyperproliferative skin diseases
WO2008051527A3 (en) Sustained release of agents for localized pain management
MX2013012038A (en) Combination of carotenoid, phytooestrogen and vitamin c for moisturizing the skin.
EA200801890A1 (en) MEANS FOR THE TREATMENT OF NOISE IN THE EARS
WO2008003484A8 (en) Agent containing chrysin and cholic acid for reducing weight, accelerating lipid catabolism, and/or restricting calories
NZ587608A (en) Use of s-adenosylmethionine (sam) and superoxide dismutase (sod) for the preparation of medicaments for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 1338628, SALIX PHARMACEUTICALS, LTD., 1700 PERIMETER PARK DRIVE, MORRISVILLE, NC 27560, US

Effective date: 20130703

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 JUN 2017 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS

Effective date: 20140908

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUN 2018 BY THOMSON REUTERS

Effective date: 20170527

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUN 2019 BY THOMSON REUTERS

Effective date: 20180509

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUN 2020 BY THOMSON REUTERS

Effective date: 20190516

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUN 2021 BY CPA GLOBAL

Effective date: 20200507

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUN 2022 BY CPA GLOBAL

Effective date: 20210429

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUN 2023 BY CPA GLOBAL

Effective date: 20220428

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUN 2024 BY CPA GLOBAL

Effective date: 20230504